[1. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974; 34:29-34.10.1016/0002-9149(74)90089-7]Open DOISearch in Google Scholar
[2. Ren J, Davidoff AJ. Diabetes rapidly induces contractile dysfunctions in isolated ventricular myocytes. Am J Physiol. 1997; 272:H148-H158.10.1152/ajpheart.1997.272.1.H1489038933]Search in Google Scholar
[3. Poornima IG, Parikh P, Shannon RP. Diabetic cardiomyopathy: The search for a unifying hypothesis. Circ Res. 2006; 98:596-605.10.1161/01.RES.0000207406.94146.c216543510]Open DOISearch in Google Scholar
[4. Bell DS. Diabetic cardiomyopathy. A unique entity or a complication of coronary artery disease? Diabetes Care. 1995; 18:708-14.10.2337/diacare.18.5.7088586013]Open DOISearch in Google Scholar
[5. Fu MX, Wells-Knecht KJ, Blackledge JA, Lyons TJ, Thorpe SR, Baynes JW. Glycation, glycoxidation, and cross-linking of collagen by glucose. Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes. 1994; 43:676-83.10.2337/diab.43.5.6768168645]Open DOISearch in Google Scholar
[6. Ma H, Li SY, Xu P, Babcock SA, Dolence EK, Brownlee M, et al. Advanced glycation endproduct (AGE) accumulation and AGE receptor up-regulation contribute to the onset of diabetic nephropathy. J Cell Mol Med. 2009; 13:1751-64.10.1111/j.1582-4934.2008.00547.x282934119602045]Open DOISearch in Google Scholar
[7. Edelstein D, Brownlee M. Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats. Diabetologia. 1992; 35:96-7.10.1007/BF004008591541387]Open DOISearch in Google Scholar
[8. Hammes HP, Brownlee M, Edelstein D, Saleck M, Martin S, Federlin K. Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat. Diabetologia. 1994; 37:32-5.10.1007/BF004287748150227]Open DOISearch in Google Scholar
[9. Cameron NE, Cotter MA, Dines K, Love A. Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotocin-diabetic rats. Diabetologia. 1992; 35:946-50.10.1007/BF004014231451951]Open DOISearch in Google Scholar
[10. Fiordaliso F, Li B, Latini R, Sonnenblick EH, Anversa P, Leri A, et al. Myocyte death in streptozotocininduced diabetes in rats in angiotensin II- dependent. Lab Invest. 2000; 80:513-27.10.1038/labinvest.378005710780668]Open DOISearch in Google Scholar
[11. Fukagawa NK, Li M, Liang P, Russell JC, Sobel BE, Absher PM. Aging and high concentrations of glucose potentiate injury to mitochondrial DNA. Free Radical Biol Med. 1999; 27:1437-43.10.1016/S0891-5849(99)00189-6]Search in Google Scholar
[12. Dunn JA, Patrick JS, Thorpe SR, Baynes JW. Oxidation of glycated proteins: age-dependent accumulation of N epsilon-(carboxymethyl)lysine in lens proteins. Biochemistry. 1989; 28:9464-8.10.1021/bi00450a0332514802]Open DOISearch in Google Scholar
[13. von Harsdorf R, Li PF, Dietz R. Signaling pathways in reactive oxygen species-induced cardiomyocyte apoptosis. Circulation. 1999; 99:2934-41.10.1161/01.CIR.99.22.293410359739]Open DOISearch in Google Scholar
[14. Cooper ME. The role of the renin-angiotensinaldosterone system in diabetes and its vascular complications. Am J Hypertension. 2004; 17:16S-20S; quiz A12-14.10.1016/j.amjhyper.2004.08.00415539106]Open DOISearch in Google Scholar
[15. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000; 355:253-9.]Search in Google Scholar
[16. Ruiz-Ortega M, Lorenzo O, Ruperez M, Egido J. ACE inhibitors and AT(1) receptor antagonists-beyond the haemodynamic effect. Nephrol Dial Transplant. 2000; 15:561-5.10.1093/ndt/15.5.56110809789]Search in Google Scholar
[17. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993; 329:1456-62.10.1056/NEJM1993111132920048413456]Search in Google Scholar
[18. Nomoto T, Nishina T, Miwa S, Tsuneyoshi H, Maruyama I, Nishimura K, et al. Angiotensinconverting enzyme inhibitor helps prevent late remodeling after left ventricular aneurysm repair in rats. Circulation. 2002; 106:I115-9.10.1161/01.cir.0000032887.55215.5c]Search in Google Scholar
[19. Wolf G, Neilson EG. Angiotensin II as a renal growth factor. J Am Soc Nephrol. 1993; 3:1531-40.10.1681/ASN.V3915318507808]Search in Google Scholar
[20. Hsu SM, Raine L, Fanger H. Use of avidin-biotinperoxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981; 29:577-80.10.1177/29.4.61666616166661]Open DOISearch in Google Scholar
[21. Moreno PR, Murcia AM, Palacio IF, Leon MN, Bernardi VH, Fuster V, et al. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation. 2000; 102:2180-4.10.1161/01.CIR.102.18.218011056089]Open DOISearch in Google Scholar
[22. Westerman D, Rutschow S, Jager S, Linderer A, Anker S, Riad A, et al. Contributions of cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiuomyopathy.The role of angiotensin receptor antagonism. Diabetes. 2007; 56:641-6.10.2337/db06-116317327431]Open DOISearch in Google Scholar
[23. Lavrentyev EN, Estes AM, Malik KU. Mechanism of high glucose induced angiotensin II production in rat vascular smooth muscle cells. Circ Res. 2007; 101: 455-64.10.1161/CIRCRESAHA.107.15185217626897]Open DOISearch in Google Scholar
[24. Berry C, Hamilton CA, Brosnan MJ, Magill FG, Berg GA, McMurray JJ, et al. Investigation into the sources of superoxide in human blood vessels: angiotensin II increases superoxide production in human internal mammary arteries. Circulation. 2000; 101:2206-12.10.1161/01.CIR.101.18.2206]Open DOISearch in Google Scholar
[25. Rueckschloss U, Quinn MT, Holtz J, Morawietz H. Dose-dependent regulation of NAD(P)H oxidase expression by angiotensin II in human endothelial cells: protective effect of angiotensin II type 1 receptor blockade in patients with coronary artery disease. Arterioscler Thromb Vasc Biol. 2002; 22:1845-51.10.1161/01.ATV.0000035392.38687.6512426214]Open DOISearch in Google Scholar
[26. Tanaka N, Yonekura H, Yamagishi S, Fujimori H, Yamamoto Y, Yamamoto H. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17betaestradiol through Sp-1 in human vascular endothelial cells. J Biol Chem. 2000; 275:25781-90.10.1074/jbc.M00123520010829018]Search in Google Scholar
[27. Adeghate E. Molecular and cellular basis of the aetiology and management of diabetic cardiomyopathy: a short review. Mol Cell Biochem. 2004; 261:187-91.10.1023/B:MCBI.0000028755.86521.11]Search in Google Scholar
[28. Miyata T, van Ypersele de Strihou C, Ueda Y, Ichimori K, Inagi R, Onogi H, et al. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J Am Soc Nephrol. 2002; 13:2478-87.10.1097/01.ASN.0000032418.67267.F2]Open DOISearch in Google Scholar
[29. Dunn JA, McCance DR, Thorpe SR, Lyons TJ, Baynes JW. Age-dependent accumulation of N epsilon-(carboxymethyl)lysine and N epsilon- (carboxymethyl)hydroxylysine in human skin collagen. Biochemistry. 1991; 30:1205-10.10.1021/bi00219a0071899338]Open DOISearch in Google Scholar
[30. Koka V. Wang W, Huang XR, Kim-Mitsuyama S, Truong LD, Lan HY. Advanced glycation end products activate a chymase-dependent angiotensin IIgenerating pathway in diabetic complication. Circulation. 2006; 113:1353-6010.1161/CIRCULATIONAHA.105.575589140150016520412]Open DOISearch in Google Scholar
[31. Davis BJ, Forbes JM, Thomas MC, Jerums G, Burns WC, Kawachi H, et al. Superior renoprotective effects of combination therapy with ACE and AGE inhibition in the diabetic spontaneously hypertensive rat. Diabetologia. 2004; 47:89-9710.1007/s00125-003-1256-814647892]Open DOISearch in Google Scholar
[32. Grandhee SK, Monnier VM. Mechanism of formation of the Maillard protein cross-link pentosidine. Glucose, fructose, and ascorbate as pentosidine precursors. J Biol Chem. 1991; 266:11649-53.10.1016/S0021-9258(18)99006-X]Search in Google Scholar
[33. Portero-Otin M, Pamplona R, Bellmunt MJ, Ruiz MC, Prat J, Salvayre R, et al. Advanced glycation end product precursors impair epidermal growth factor receptor signaling. Diabetes. 2002; 51:1535-42.10.2337/diabetes.51.5.153511978653]Open DOISearch in Google Scholar